GermanyGermany

German and Swedish Cancer Researchers Join Forces

23.11.2003

Erlangen/Stockholm - The German biotech company responsif GmbH and scientists from the prestigious Karolinska Institute in Stockholm, Sweden, have recently signed a cooperation agreement, which will bring a promising new treatment for cancer one step closer to clinical trials. The Swedish cancer researchers working in the Department of Oncology & Pathology in the Section for Experimental Oncology are now using an “anchoring” technique developed by responsif to pack tumour antigens into virus capsoids. The aim is to create an anti-tumour vaccine, which will mobilise the body's own immune defences against cancer cells.
As part of the cooperation agreement, the Swedish scientists have obtained a license option for the specific use of the anchor technology. The agreement also gives them the option of acquiring industrial partners within the next two years to assist them in developing this technology up to market maturity.
“Our consistent patent strategy has proved to be the right one”, commented Dr. Christian Reiser, Managing Director of responsif, recently at the BioTechnica in Hannover, Germany. “We are very pleased that these clinicians plan to deploy the anchor technology developed by responsif in the battle against cancer.”
With the licensing agreement, the two partners have also entered into a scientific collaboration aimed at advancing the preclinical investigation of an anti-tumour vaccine based on the viral capsoid technology developed by the biotechnologists in Erlangen. The capsoid technology evolved from the idea of using Polyoma virus-like particles (VLPs) as delivery systems for tumour antigens. Since these particles do not contain any viral genetic information, moreover, they are not infectious.
In addition to the anchor technology, responsif GmbH is working on another immunotherapeutic approach using autologous cancer cells from patients with advanced stage cancer. The company is a spin-off of the former Division of Molecular Therapy at november AG, a biotech company traded in the Prime Standard segment of the German Stock Exchange.

Germany, SpainGermany

16.09.2006

Barcelona/Heidelberg – Based at the research park’s beachfront, the new EMBL/CRG Systems Biology Research Unit will begin work headed by renowned researcher Luis Serrano, currently co-ordinator of the EMBL Structural and...

GermanyGermany

16.09.2006

Göttingen/Bielefeld – German researchers have published the 3,12014 Mb genome of the most common natural oil-eating bacterium Alcanivorax borkumensis. Together with other measures the microbe can help to degrade marine oil spills...

GermanyGermany

16.09.2006

Würzburg – Results from recent animal studies may be bad news for Sanofi-Aventis’ (Strasbourg) new obesitas drug Acomplia, the very first inhibitor of the human endocannabinoid receptor CB1. CB1 inacivation in mice lifted their...

GermanyGermany

21.07.2006

Frankfurt – In Germany, four biotech companies will debut on the exchange list. In May, GeneArt AG of Regensburg went public on the Entry Standard, an OTC segment of the Frankfurt Stock Exchange, raising Euro23.3 million. GeneArt...

GermanyGermany

21.07.2006

Berlin – The German Federal ministry for economics and technology will support founders from universities with Euro35 million spread over the coming five years. Universities will be allowed to motivate and qualify students and...

GermanyGermany

21.07.2006

Heidelberg – The management of the former Invitrogen subsidiary BioReliance Manufacturing GmbH has bought the assets of the Heidelberg-based contract manu-facturer from the American parent company. The consortium was headed by...

GermanyGermany

21.07.2006

Berlin – Together with trade associations, Germany’s minister for agriculture, Horst Seehofer, has found a compromise solution on a new version of the current genetic engineering law. The agreement forsees an abandoning of the...

GermanyGermany

21.07.2006

Holzkirchen – One month after European authorities gave the green light for the marketing of Sandoz’ recombinant follow-on growth hormone Omnitrope in Europe, the US Food and Drug administration has approved the compound in the...

GermanyGermany

21.07.2006

German researchers are keeping their position at the forefront of research on the mechanisms of RNA interference (RNAi). Following the work of Alnylam co-founder Tom Tuschl , who deciphered the mechanism of post-transcriptional...

Germany, SpainGermany

21.07.2006

Heidelberg/Barcelona – Scientists from Centre de Regulacio Genomica in Barcelona and the EMBL in Heidelberg have identified a new part of the proofreading system that helps ensure that a gene‘s information is correctly made into...

Displaying results 291 to 300 out of 454

< Previous 291-300 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/29/article/german-and-swedish-cancer-researchers-join-forces.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products